Incretin-based therapies, such as injectable GLP-1 receptor agonists (GLP-1 RAs) and oral dipeptidyl peptidase-4 (DPP-4) inhibitors, are being increasingly utilized in the management of T2DM [6]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.